WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors.
"Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.
Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compliance and data protection functions. Before that, she was an attorney representing pharmaceutical companies and healthcare organizations.
"I believe Comera's SQore platform holds significant potential for partnership and pipeline opportunities and I look forward to working with the leadership team and my fellow Board members to advance Comera's growth and corporate strategy," Ms. Clarke said.
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.